Table 1.
Demographical Information
| All Patients (n = 46) | Male (n = 31) | Female (n = 15) | |
|---|---|---|---|
| Age in years, M (range) | 48.5 (23–78) | 48.2 (26–78) | 49.0 (23–69) |
| Ethnicity | |||
| White | 15 (32.6%) | 10 (21.7%) | 5 (10.9%) |
| Black | 11 (23.9%) | 8 (17.4%) | 3 (6.5%) |
| Asian | 18 (39.1%) | 12 (26.1%) | 6 (13.0%) |
| Other | 2 (4.3%) | 1 (2.2%) | 1 (2.2%) |
| Diagnosis | |||
| Schizophrenia | 39 (84.8%) | 26 (56.5%) | 13 (28.3%) |
| Schizoaffective Disorder | 7 (15.2%) | 5 (10.9%) | 2 (4.3%) |
| Length of PP1M use in months, M; range (SD) | 47.0; 3–102 (SD 31.5) | 52.2; 4–102 (SD 31.7) | 36.4; 3–88 (SD 29.3) |
| Hospitalisations 1 year pre-PP3M initiation | |||
| No | 37 (80.4%) | 27 (58.7%) | 10 (21.7%) |
| Yes | 9 (19.6%) | 4 (8.7%) | 5 (10.9%) |
| Hospitalisations 1 year post-PP3M initiation | |||
| No | 43 (93.5%) | 28 (60.9%) | 15 (32.6%) |
| Yes | 3 (6.5%) | 3 (6.5%) | 0 (0%) |